Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G/A

Emergent Biosolutions, Inc.

EBSNYSEEQUITYCurrent

Beneficial Ownership Report

Filed Nov 16, 2026Accepted Nov 16, 2026, 2:30 PM ESTFiling CIK 1367644Accession 0000919574-26-008077
Share

Structured filing — SCHEDULE 13G/A

primary_doc.xml

Open full document ↗

Amendment · This filing reports the amendment as submitted.

Subject company

Company
Emergent BioSolutions Inc.
Company CIK
0001367644
Street
300 PROFESSIONAL DR
City
GAITHERSBURG
State / country code
MD
Postal code
20879

Statement details

Amendment number
1
Security class
Common Stock, par value $0.001 per share
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
Oak Hill Advisors LP
Citizenship / organization
DE
Reporting person type
IA · PN
Aggregate amount owned
4,014,015.00
Percent of class
7.5
Sole voting power
4,014,015.00
Shared voting power
0.00
Sole dispositive power
4,014,015.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N
Comments
Includes 2,500,000 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.

Item 1

Issuer

Emergent BioSolutions Inc.

Principal executive office address

300 Professional Drive, Gaithersburg, MD 20879

Item 2

Citizenship

OHA is a Delaware limited partnership.

Filing person

This Schedule 13G is being filed on behalf of Oak Hill Advisors, L.P., a Delaware limited partnership ("OHA" or, the "Reporting Person"), as investment adviser to certain funds and client accounts (directly or through an affiliate) (together, the "Oak Hill Funds"), with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Emergent BioSolutions Inc. (the "Company"), and the shares of Common Stock issuable upon exercise of warrants, directly held by the Oak Hill Funds. OHA is a subsidiary business of T. Rowe Price Associates, Inc. ("TRP"). OHA's beneficial ownership does not include any shares that may be beneficially owned by TRP. Glenn R. August, a United States citizen, is the Founder and Chief Executive Officer of OHA. Any disclosures herein with respect to persons other than the Reporting Person are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed in and of itself as an admission by the Reporting Person as to beneficial ownership of the securities reported herein.

Principal business or residence address

The address of the business office of the Reporting Person is One Vanderbilt Avenue, 16th Floor, New York, New York 10017.

Item 3

Not applicable indication

N

Type of filing person

IA

Item 4

Percent of class

7.5%

Amount beneficially owned

The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 51,273,336 shares of Common Stock outstanding as of July 30, 2026, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026, and assumes the exercise of the warrants reported herein.

Sole voting power

The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

Shared voting power

The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

Sole dispositive power

The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

Shared dispositive power

The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

N

Ownership on behalf of another person

See Item 2(a). The Oak Hill Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
Oak Hill Advisors LP
Signed
/s/ William H. Bohnsack, Jr.
Title
William H. Bohnsack, Jr., Authorized Signatory
Date
11/16/2026

Company context

Joseph Papa President and Chief Executive Officer Richard Lindahl EVP, Chief Financial Officer and Treasurer Jessica Perl SVP, General Counsel and Corporate Secretary Paul Williams SVP, Products Business Coleen Glessner EVP, Quality, Ethics and Compliance Simon Lowry, M.D. Chief Medical Officer, Head of Research and Development Stephanie Duatschek SVP, Chief Strategy and Transformation Officer Michelle Pepin SVP, Chief Human Resources Officer Bill Hartzel SVP, Manufacturing and Bioservices Emergent’s Executive Management Team

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by AMERICAN CENTURY INVESTMENT MANAGEMENT INC regarding Emergent BioSolutions Inc.Nov 16, 2026
  2. Other EventsNov 4, 2026
  3. 10-Q filingNov 3, 2026
  4. Results of Operations and Financial Condition · Regulation FD DisclosureNov 2, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 16, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.